Aquatic Capital Management LLC Makes New Investment in Dr. Reddy's Laboratories Limited (NYSE:RDY)

Aquatic Capital Management LLC bought a new stake in shares of Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 34,370 shares of the company's stock, valued at approximately $543,000.

Several other large investors also recently modified their holdings of the stock. Robeco Institutional Asset Management B.V. lifted its position in Dr. Reddy's Laboratories by 453.8% during the fourth quarter. Robeco Institutional Asset Management B.V. now owns 11,438,908 shares of the company's stock worth $180,620,000 after purchasing an additional 9,373,412 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Dr. Reddy's Laboratories by 382.9% during the 4th quarter. Renaissance Technologies LLC now owns 9,418,428 shares of the company's stock worth $148,717,000 after acquiring an additional 7,467,979 shares during the period. Aikya Investment Management Ltd boosted its position in shares of Dr. Reddy's Laboratories by 416.1% during the 4th quarter. Aikya Investment Management Ltd now owns 5,610,503 shares of the company's stock worth $88,590,000 after acquiring an additional 4,523,303 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Dr. Reddy's Laboratories by 405.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 5,361,013 shares of the company's stock valued at $84,643,000 after acquiring an additional 4,301,212 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in Dr. Reddy's Laboratories by 397.2% during the fourth quarter. Vanguard Group Inc. now owns 4,896,185 shares of the company's stock valued at $77,311,000 after purchasing an additional 3,911,404 shares in the last quarter. 3.85% of the stock is owned by institutional investors and hedge funds.

Dr. Reddy's Laboratories Trading Down 0.5 %

Shares of RDY stock opened at $13.85 on Friday. Dr. Reddy's Laboratories Limited has a fifty-two week low of $12.26 and a fifty-two week high of $16.89. The stock's fifty day moving average price is $13.21 and its two-hundred day moving average price is $14.18. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.38 and a current ratio of 1.92. The company has a market cap of $11.56 billion, a PE ratio of 22.05 and a beta of 0.51.

Dr. Reddy's Laboratories (NYSE:RDY - Get Free Report) last released its earnings results on Thursday, January 23rd. The company reported $0.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.19 by $0.01. Dr. Reddy's Laboratories had a return on equity of 17.87% and a net margin of 17.25%. Equities analysts predict that Dr. Reddy's Laboratories Limited will post 0.8 EPS for the current fiscal year.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.

Want to see what other hedge funds are holding RDY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.